Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Is Beyond Meat Stock a Buy in the ‘Sixties?’

By Will Ashworth, InvestorPlace Contributor

The volatility stemming from the impact and uncertainty of the coronavirus will likely put a cap on Beyond Meat stock. But once the dark clouds clear, BYND has excellent growth potential.

Consider This One Investment Instead of Buying the Comcast Stock Dip

By Will Ashworth, InvestorPlace Contributor

While Ramer would disagree with this assessment, the general sentiment that Comcast remains a good buy within the telecom and media industries is not a unique one. For every negative due to revenue losses from the coronavirus, analysts argue a business such as Comcast’s may benefit from people staying home and using some of its products and services.

I Doubt You’ll See Warren Buffett Buying IBIO Stock

By Will Ashworth, InvestorPlace Contributor

And, yet, you won’t see Buffett buying iBio despite the fact it’s working on a coronavirus vaccine. You won’t for several primary reasons. 

A 6.2% Yield Makes WFC Stock Attractive, but Its Culture Is Worrisome

By Will Ashworth, InvestorPlace Contributor

At 20, even if an investment in Wells Fargo goes south, a young investor has plenty of time to recover those losses. And, yes, it’s possible that Scharf will be the person to right the ship, recouping a big chunk of Warren Buffett’s recent paper losses.

Pfizer Stock Remains a Cautionary Tale For Investors

By Will Ashworth, InvestorPlace Contributor

Pfizer has seriously underperformed in recent years. Down 10.8% year to date, Pfizer stock remains an underdog.

Load More